Program and Abstracts of Annual Meeting of the Japanese Society for Medical Mycology
Print ISSN : 0916-4804
Search
Advanced search
OR
Browse
Search
The 50th Annual Meeting of the Japanese Society for Medical Mycology
Displaying 1-50 of 133 articles from this issue
Show all abstracts
The 50th Annual Meeting of the Japanese Society for Medical Mycology
Invitation Lecture
  • Trends in the epidemiology of invasive fungal infections
    David W. Warnock
    Session ID: IL
    Published: 2006
    Released on J-STAGE: September 12, 2006
    DOIhttps://doi.org/10.11534/jsmm.50.0.1.0
    CONFERENCE PROCEEDINGS FREE ACCESS
    Show abstractHide abstract
    The last two decades have seen unprecedented changes in the pattern of serious fungal disease. Infections with the major opportunistic pathogens are increasing in incidence, new pathogens are being reported in unprecedented numbers, and drug-resistant pathogens are emerging. The HIV epidemic is a major factor that has contributed to the dramatic increase in the occurrence of IFI, but medical developments, such as the widespread use of immunosuppressive agents in transplantation and cancer treatment, have also resulted in an increase in size of the population at risk.

    Enhanced surveillance is essential to improve our understanding of the epidemiology of IFI. Although passive surveillance has been conducted in a number of countries, this often underestimates incidence rates and healthcare costs, and can lead to inaccurate description of risk factors for fungal diseases. Active surveillance is expensive and difficult to conduct, but it has enabled accurate incidence rates to be determined for a number of opportunistic IFI.

    Sentinel and population-based surveillance programs have documented significant changes in the rates of Candida bloodstream infections (BSI) among different patient groups, with the emergence of non-albicans Candida species as important pathogens. More cases of Candida BSI now occur among critical care patients than are diagnosed among neutropenic cancer patients or stem cell transplant (SCT) recipients. C. glabrata has become the second most common cause of Candida BSI in the USA, now accounting for 20-25% of cases. However, for reasons that are not well understood, C. glabrata remains an infrequent cause of Candida BSI in Latin America and Asia, where C. parapsilosis is the second most frequent organism. The emergence of C. glabrata as an important cause of Candida BSI is of concern because of reports that about 10% of incident bloodstream isolates of this species are resistant to fluconazole.

    An uncommon infection before the HIV epidemic, cryptococcosis has emerged as an important cause of illness and death among persons with AIDS. In the USA, population-based surveillance documented the declining incidence of cryptococcosis during the 1990s, largely as a result of improvements in antiretroviral drug treatment. In contrast, in resource-limited countries with large HIV epidemics, the burden of this disease is increasing.

    Surveillance programs have begun to provide important information about the incidence of invasive aspergillosis (IA) and other serious IFI after SCT. In a report from the TransNet program, the aggregate cumulative incidence of IA at 19 transplant centers throughout the USA, in 2001 and 2002, ranged from 0.5% after autologous SCT, to 3.9% after transplantation from an unrelated donor. Wide variations in incidence were seen between different centers. Many factors could account for this, including variations in rates of follow-up and diagnostic practices between sites. Transplant- and host-related factors may also impact the incidence of IA at individual centers.

    A number of other IFI have been seen after SCT. Between 2001 and 2003, IA, zygomycosis and fusariosis accounted for 68%, 8%, and 6%, respectively, of the identified mould infections reported to the TransNet program.

    IFI exact a tremendous toll in terms of human life and healthcare costs, despite the fact that these diseases are still under-diagnosed. Establishing and maintaining surveillance programs for IFI, both on a national basis and within individual medical centers, will be essential if we are to determine the burden posed by these diseases. Together with risk-factor studies and cost-effectiveness analyses, this should provide the information needed to develop appropriate intervention and prevention strategies.

    View full abstract
The Fiftieth Anniversary of Menorial Lecture
Luncheon Seminar I
Luncheon Seminar II
Luncheon Seminar III
Luncheon Seminar IV
Evening Seminar I
  • Recent guidelines for the diagnosis and treatment of aspergillosis
    John E. Bennett
    Session ID: EI
    Published: 2006
    Released on J-STAGE: September 12, 2006
    DOIhttps://doi.org/10.11534/jsmm.50.0.11.0
    CONFERENCE PROCEEDINGS FREE ACCESS
    Show abstractHide abstract
    The diagnostic guidelines for invasive aspergillosis have recently been revised by the EORTC-MSG, a European-USA group of clinical investigators. The purpose of the guidelines is to provide a consensus that is reproducible and feasible to perform for clinical trials of antifungal agents. The category of "probable" aspergillosis is to include patients with early disease that should receive antifungal therapy despite absence of firm proof of diagnosis. Patients in this group are defined by (1) an immunodepressed state that increases risk of aspergillosis, (2) clinical findings consistent with this mycosis and (3) microbiologic evidence of a mould infection. One change in the criteria from the prior guidelines was to upgrade the significance of bronchoalveolar lavage cultures and specific thoracic CT findings in patients at very high risk of aspergillosis. These patients are recipients of allogeneic hematopoietic stem cell transplant or have had prolonged, severe neutropenia. Another change was to recognize the utility of galactomannan and glucan testing, although definitions of what constitutes a positive test have not yet been decided.
    The guidelines from the Infectious Diseases Society of America omit diagnostic criteria but provide detailed treatment recommendations for the different clinical forms of aspergillosis, as well as brief recommendations about empirical therapy and prophylaxis. Voriconazole is recommended as the treatment of choice for most clinical forms of invasive aspergillosis, with alternatives including a lipid formulation of amphotericin B, itraconazole or caspofungin. Reduction of immunosuppression is advocated as vitally important. Surgery has a role for selected conditions.
    View full abstract
Evening Seminar II
Poster
feedback
 Top